2017 Press Releases

Keyword Search
 
DateTitle 
08/03/17Neurocrine Biosciences Reports Second Quarter 2017 Results
- INGREZZA® Net Product Sales of $6.3 Million in Initial Two Months of Commercialization as the First and Only U.S. Food and Drug Administration Approved Product for the Treatment of Tardive Dyskinesia - Partner AbbVie Expected to Submit Elagolix NDA for Endometriosis During the Third Quarter of 2017 and Pay $30 Million Milestone in Fourth Quarter of 2017 - Partner Mitsubishi Tanabe Expected to Initiate Pivotal Trial of INGREZZA in Asia for the Treatment of Tardive Dyskinesia and Pay $15 M... 
Printer Friendly Version
07/28/17Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2017 Results
Conference Call and Webcast Scheduled for August 3, 2017 SAN DIEGO, July 28, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report second quarter 2017 results after the Nasdaq market close on August 3, 2017.  Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update that day at 5:00pm Eastern Time (2:00pm Pacific Time). Participants can access the live conference call by... 
Printer Friendly Version
07/21/17Neurocrine Biosciences Announces the Appointment of Julie Cooke as Chief People Officer
SAN DIEGO, July 21, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurological and endocrine related disorders, announced that Julie Cooke is joining as Chief People Officer in September 2017 and will be a member of the Management Committee.   "Neurocrine is delighted to welcome Julie Cooke as our Chief People Officer to lead our Human Resource function," said David-Alexandre C. Gros, President and Chief Operating Officer of Neurocrine Bi... 
Printer Friendly Version
06/09/17Neurocrine Biosciences to Present at the Goldman Sachs 38th Annual Global Healthcare Conference
Live Audio Webcast Will be on June 15, 2017 SAN DIEGO, June 9, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, CEO of Neurocrine Biosciences, will be presenting at the Goldman Sachs 38th Annual Global Healthcare Conference in Rancho Palos Verdes, CA. The live presentation takes place on Thursday, June 15 at 9:20am PT (12:20pm ET).  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com. ... 
Printer Friendly Version
06/02/17Neurocrine Announces Presentations Related to INGREZZA® (valbenazine) Capsules at the 21st International Congress of Parkinson's Disease and Movement Disorders
SAN DIEGO, June 2, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today the upcoming presentation of three posters at the 21st International Congress of Parkinson's Disease and Movement Disorders (MDS), including data from the KINECT 3 Phase III extension study of INGREZZA® (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD). The 21st International Congress of Parkinson's Disease and Movement Disorders will take place in Vancouver BC, C... 
Printer Friendly Version
06/01/17Neurocrine Biosciences to Present at the Jefferies 2017 Global Healthcare Conference
Live Audio Webcast Will be on June 8, 2017 SAN DIEGO, June 1, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, CEO of Neurocrine Biosciences, will be presenting at the Jefferies 2017 Global Healthcare Conference in New York City. The live presentation takes place on Thursday, June 8 at 1:30pm ET (10:30am PT).  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.   Listeners are enc... 
Printer Friendly Version
05/23/17Neurocrine Announces Phase II Results of VMAT2 Inhibitor INGREZZA® For Treatment of Tourette Syndrome
Study Provides Clear Path Forward for Future Pivotal Studies Company to Host Conference Call and Webcast Tuesday, May 23rd at 5:00 P.M. ET / 2:00 P.M. PT SAN DIEGO, May 23, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the initial Phase II Tourette syndrome T-Force GREEN study of INGREZZA®(valbenazine), a small molecule VMAT2 inhibitor, did not meet its primary endpoint. The pre-specified primary endpoint was the change-from-baseline between the plac... 
Printer Friendly Version
05/18/17Neurocrine Announces INGREZZA® (valbenazine) Capsules Pharmacokinetic Profile and Long-Term Data to be Presented at the 2017 American Psychiatric Association Annual Meeting
SAN DIEGO, May 18, 2017 /PRNewswire/ -- Neurocrine Biosciences Inc. (NASDAQ: NBIX) announced today the upcoming presentation at the American Psychiatric Association (APA) Annual Meeting of pharmacokinetic data, as well as long-term data from the KINECT 3 Phase III extension study of INGREZZA® (valbenazine) capsules for the treatment of adults with TD. "This year's annual meeting of the APA is an excellent opportunity to present additional data and analyses from the extensive clinical develop... 
Printer Friendly Version
05/17/17AbbVie Presents Pivotal Phase 3 Data on Investigational Treatment Elagolix at the World Congress on Endometriosis
- Primary and secondary efficacy and safety data to be presented from two pivotal Phase 3 studies evaluating the use of elagolix in endometriosis-associated pain - New hormone and ovulation data will also be presented from a Phase 1 clinical study NORTH CHICAGO, Ill., May 17, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced that data from two replicate Phase 3 st... 
Printer Friendly Version
05/11/17Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference
Live Audio Webcast Will be on May 17, 2017 SAN DIEGO, May 11, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, CEO of Neurocrine Biosciences, will be presenting at the Bank of America Merrill Lynch 2017 Healthcare Conference in Las Vegas. The live presentation takes place on Wednesday, May 17 at 8:40am PT (11:40am ET).  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.   Listene... 
Printer Friendly Version
05/09/17Neurocrine Biosciences Reports First Quarter 2017 Results
- Launched INGREZZA® Commercially after Approval by the U.S. Food and Drug Administration for the Treatment of Tardive Dyskinesia - Phase II Study Results of INGREZZA in Pediatric Tourette Syndrome Expected in May 2017 - Acquired U.S. and Canadian Rights to Opicapone for Parkinson's Disease - Partner AbbVie Expected to Submit New Drug Application for Elagolix in Third Quarter of 2017 and Report Phase III Results in Uterine Fibroids by End of Year SAN DIEGO, May 9, 2017 /PRNewswire/ -... 
Printer Friendly Version
05/03/17Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2017 Results
Conference Call and Webcast Scheduled for Tuesday, May 9, 2017 SAN DIEGO, May 3, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report first quarter 2017 results after Nasdaq market close on Tuesday, May 9, 2017.  Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Tuesday afternoon, May 9, 2017, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Participants can ... 
Printer Friendly Version
05/02/17Neurocrine Biosciences, Inc. Announces Closing of Offering of $517.5 Million of Convertible Senior Notes
SAN DIEGO, May 2, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has completed its previously announced private offering of $517.5 million aggregate principal amount of its 2.25% convertible senior notes due 2024 (the "notes"), which includes $67.5 million aggregate principal amount of notes that were sold pursuant to the exercise of the initial purchasers' option to purchase additional notes.  The notes were sold to qualified institutional buyers pursua... 
Printer Friendly Version
04/26/17Neurocrine Biosciences, Inc. Prices $450.0 Million Convertible Senior Notes Offering
SAN DIEGO, April 26, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today the pricing of its offering of $450.0 million aggregate principal amount of 2.25% convertible senior notes due 2024 (the "notes"). The notes will be sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The sale of the notes is expected to close on May 2, 2017, subject to customary closing condition... 
Printer Friendly Version
04/25/17Neurocrine Announces Proposed Convertible Senior Notes Offering
SAN DIEGO, April 25, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its intention to offer, subject to market and other conditions, $450.0 million aggregate principal amount of convertible senior notes due 2024 (the "notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Neurocrine also expects to grant the initial purchasers of the notes a 30-day option to purcha... 
Printer Friendly Version
04/21/17Neurocrine Announces INGREZZA™ Long-Term Safety and Efficacy Data to be Presented at the 2017 American Academy of Neurology Annual Meeting
Additional results from largest ever clinical program in tardive dyskinesia to be highlighted as platform and poster presentations SAN DIEGO, April 21, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that long-term safety and efficacy data from the KINECT 3 Phase III extension study of INGREZZA™ (valbenazine) capsules for the treatment of adults with tardive dyskinesia will be presented as a platform presentation at the American Academy of Neurology (AAN) Annu... 
Printer Friendly Version
04/11/17Neurocrine Announces FDA Approval of INGREZZA TM (valbenazine) Capsules as the First and Only Approved Treatment for Adults with Tardive Dyskinesia (TD)
Provides significant and rapid reduction in involuntary movements with simple once-daily dosing Enables treatment of TD with commonly prescribed psychiatric medication regimens Investor conference call and webcast scheduled for today at 5:30 pm ET (2:30 pm PT) SAN DIEGO, April 11, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the U.S. Food and Drug Administration (FDA) has approved INGREZZATM (valbenazine) capsules for the treatment of adults with... 
Printer Friendly Version
03/21/17Neurocrine Announces American Journal of Psychiatry Publication of Positive Results from Kinect 3 Phase III Study of INGREZZA TM (valbenazine) for the Treatment of Tardive Dyskinesia
- Phase III study conducted in patients with tardive dyskinesia shows significant and meaningful reduction in symptoms with INGREZZA - INGREZZA clinical development program is largest ever in tardive dyskinesia with over 1,000 persons having participated in 20 clinical trials SAN DIEGO, March 21, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurologic, psychiatric and endocrine related disorders, announced today that positive result... 
Printer Friendly Version
02/14/17Neurocrine Biosciences Reports Year-End 2016 Results and Provides Investor Update for 2017
INGREZZATM New Drug Application PDUFA Action Date of April 11, 2017 Acquired U.S. Rights to Opicapone for Parkinson's Disease Elagolix New Drug Application Submission for Endometriosis Expected in Third Quarter of 2017 Two Phase III Studies of Elagolix in Uterine Fibroids Underway, Top-Line Data End of Year Phase II Study of Valbenazine in Pediatric Tourette Syndrome Expected to Readout in Second Quarter 2017 Phase II Trial for Essential Tremor Drug Candidate NBI-640756 Planned fo... 
Printer Friendly Version
02/09/17Neurocrine and BIAL Announce Exclusive North American Licensing Agreement for Opicapone
Expands Movement Disorder Franchise with Rights to Commercialize Late Stage Asset for Parkinson's Disease ONGENTYS® (opicapone) Approved in Europe in June 2016 Neurocrine to Host Conference Call and Webcast Today at 4:30pm ET/ 1:30pm PT SAN DIEGO and PORTO, Portugal, Feb. 9, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and BIAL today announced that they have entered into an exclusive licensing agreement for the development and commercialization of opicapone in North ... 
Printer Friendly Version
02/07/17Neurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2016 Results
Conference Call and Webcast Scheduled for Tuesday, February 14, 2017 SAN DIEGO, Feb. 7, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its fourth quarter 2016 results after the Nasdaq market closes on Tuesday, February 14, 2017.  Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Tuesday afternoon, February 14, 2017 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific... 
Printer Friendly Version
01/17/17Neurocrine Announces Completion of Phase II Clinical Study of VMAT2 Inhibitor INGREZZA™ (valbenazine) in Adults with Tourette Syndrome
Eight Week Study Assessed Safety, Tolerability and Efficacy in 124 Adult Subjects Company to Host Conference Call and Webcast Today at 4:30pm ET/ 1:30pm PT SAN DIEGO, Jan. 17, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today the top-line results from the Company's Phase II T-Forward study of INGREZZA™ (valbenazine), a highly-selective small molecule Vesicular Monoamine Transporter 2 (VMAT2) inhibitor, in adults with Tourette syndrome. While the study showed ... 
Printer Friendly Version
01/06/17Neurocrine Biosciences Announces the Appointment of David-Alexandre Gros M.D. President and Chief Operating Officer
SAN DIEGO, Jan. 6, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurological and endocrine related disorders, announced that David-Alexandre "DA" Gros M.D. has joined the executive management team as President and Chief Operating Officer.   "Neurocrine is very pleased to welcome Dr. Gros as our President and Chief Operating Officer as we move forward with our transformation into a commercial entity," said Kevin Gorman, Chief Executive Of... 
Printer Friendly Version
01/05/17Neurocrine Provides Update on FDA Advisory Committee for INGREZZA™ (valbenazine) for the Treatment of Tardive Dyskinesia
Company to Host Conference Call and Webcast Today, January 5th at 4:30pm ET / 1:30pm PT SAN DIEGO, Jan. 5, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that the U.S. Food and Drug Administration (FDA), after further review of the INGREZZA™ (valbenazine) New Drug Application (NDA), has decided to cancel the Psychopharmacologic Drugs Advisory Committee meeting which was originally scheduled for February 16, 2017. The FDA informed the Company that the Priority... 
Printer Friendly Version
01/03/17Neurocrine Biosciences to Present at the 35th Annual J.P. Morgan Healthcare Conference
Live Audio Webcast will be on January 9, 2017 SAN DIEGO, Jan. 3, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco. The live presentation takes place on Monday, January 9 at 2:30pm PT (5:30pm ET).  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.   ... 
Printer Friendly Version